Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:CDTX News 14 November 2025 - 9 January 2026

Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck shares rose 0.4% to $111.41 Friday after a report said it is in talks to buy Revolution Medicines for $28–32 billion. Revolution shares jumped 16% in extended trading. Merck just completed a $221.50-per-share tender offer for Cidara Therapeutics and said the deal will raise 2026 R&D expense by $9 billion. Analysts warned U.S. vaccine policy changes could cut Merck revenue by $2 billion annually.
9 January 2026
···
Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck shares rose 1.5% to $110.20 after Wolfe Research upgraded the stock and set a $135 price target. Merck completed its $221.50-per-share tender offer for Cidara and flagged a $9 billion R&D charge for 2026. Investors watched fallout from a U.S. shift to a single-dose HPV vaccine recommendation ahead of Merck’s Feb. 3 results.
8 January 2026
····
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck shares slipped 0.2% in after-hours trading after U.S. health officials cut HPV vaccine guidance to one dose, raising concerns over Gardasil sales. Analysts warned the change could reduce 2026 Gardasil revenue by up to $630 million. Merck also completed its $9.2 billion Cidara acquisition and set Feb. 3 for quarterly results.
8 January 2026
····
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck shares slipped 0.3% to $108.59 after it completed its tender offer for Cidara Therapeutics and expects to finalize the $9.2 billion acquisition later Wednesday. The deal will add about $9 billion to 2026 R&D expenses and reduce earnings per share by 30 cents in the first year. Merck also began a Phase 3 lung-cancer trial of calderasib with Keytruda QLEX. U.S. officials updated HPV and rotavirus vaccine guidance this week.
7 January 2026
·····
Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

Merck shares rose 1.2% to $106.45 Friday after Nasdaq set Jan. 6 as the expiration for its $9.2 billion cash tender offer for Cidara Therapeutics. Cidara shares will be halted after Jan. 6 and suspended Jan. 8 if the merger closes as planned. Merck’s move snapped a three-day losing streak, leaving the stock just below its 52-week high. About 10 million shares traded, below the 50-day average.
3 January 2026
···
Merck Stock (MRK) News and Forecasts: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Cidara Acquisition in Focus Ahead of the Next Market Session

Merck Stock (MRK) News and Forecasts: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Cidara Acquisition in Focus Ahead of the Next Market Session

U.S. stock markets are closed for the weekend as of 2:34 a.m. ET Saturday. Merck last traded near $106.78, up 0.33%. The company is in focus after joining TrumpRx-linked drug pricing deals and announcing 70% discounts on diabetes drugs for U.S. consumers. Trading volume remains thin following a flat Friday session.
27 December 2025
···
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Merck’s $9.2 Billion Bid Sends Cidara Therapeutics (CDTX) Soaring 105% on November 14, 2025

Cidara Therapeutics, Inc. (NASDAQ: CDTX) is at the center of Wall Street’s attention today after Merck & Co., Inc. (NYSE: MRK) agreed to acquire the San Diego–based biotech in a cash deal valued at approximately $9.2 billion, sending CDTX shares more than 100% higher in a single session. Reuters+1 Below is a detailed look at today’s news (14 November 2025), the science behind Cidara’s lead flu-prevention asset CD388, the stock market reaction, and the wave of shareholder-law-firm investigations that emerged within hours of the announcement. Merck to Acquire Cidara for $221.50 Per Share in Cash Merck and Cidara announced this
14 November 2025
··

Stock Market Today

Airbus stock price ends higher near 191 euros as January deliveries slow, earnings loom

Airbus stock price ends higher near 191 euros as January deliveries slow, earnings loom

8 February 2026
Airbus shares rose 0.94% to 191.30 euros Friday as the company reported 19 aircraft deliveries in January, down from 25 a year earlier. Supply chain bottlenecks remain an issue, with executives at the Singapore Airshow calling delays “unacceptable.” Jefferies kept a Neutral rating and a 215-euro price target. Airbus will report full-year 2025 results on Feb. 19.
Banco Santander stock heads into Monday after Friday bounce as buyback and Webster deal loom

Banco Santander stock heads into Monday after Friday bounce as buyback and Webster deal loom

8 February 2026
Banco Santander shares closed up 1.85% at €10.66 in Madrid Friday after launching a €5.03 billion buyback and agreeing to acquire U.S. lender Webster Financial for $12.2 billion. Santander said its board will review the 2025 cash dividend proposal on Feb. 24. The bank also raised its UK motor finance redress provision to £461 million amid regulatory uncertainty.
Go toTop